Perspective Therapeutics (CATX) 10-Q 12 Feb 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 11, 2020
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	0000728387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		67,650,547
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common stock, $0.001
Entity Interactive Data Current	Yes

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 3,180	$ 5,326
Accounts receivable, net	1,409	1,154
Inventory	545	530
Prepaid expenses and other current assets	497	305
Total current assets	5,631	7,315
Property and equipment, net	1,736	1,609
Right of use asset, net (Note 9)	1,116
Restricted cash	181	181
Inventory, non-current	127	155
Other assets, net of accumulated amortization	142	162
Total assets	8,933	9,422
Current liabilities:
Accounts payable and accrued expenses	632	683
Lease liability (Note 9)	229
Accrued protocol expense	24	133
Accrued radioactive waste disposal	89	74
Accrued payroll and related taxes	203	89
Accrued vacation	163	142
Total current liabilities	1,340	1,121
Long-term liabilities:
Non-current Lease Liability	889
Asset retirement obligation	563	621
Total liabilities	2,792	1,742
Commitments and contingencies (Note 7)
Shareholders' equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 shares issued and outstanding	67	67
Additional paid-in capital	92,279	92,105
Accumulated deficit	(86,205)	(84,492)
Total shareholders' equity	6,141	7,680
Total liabilities and shareholders' equity	8,933	9,422
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	67,388,047	67,388,047
Common stock, shares outstanding (in shares)	67,388,047	67,388,047
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Sales, net	$ 2,206,000	$ 1,904,000	$ 4,521,000	$ 3,466,000
Cost of sales	1,095,000	1,139,000	2,174,000	2,177,000
Gross profit	1,111,000	765,000	2,347,000	1,289,000
Research and development:
Proprietary research and development	277,000	395,000	510,000	789,000
Collaboration arrangement, net of reimbursement		19,000		45,000
Total research and development	277,000	414,000	510,000	834,000
Sales and marketing	666,000	702,000	1,481,000	1,351,000
(Gain) on equipment disposal		(23,000)		(23,000)
General and administrative	1,071,000	1,101,000	2,168,000	2,074,000
(Gain) on change in estimate of asset retirement obligation (Note 9)			(73,000)
Total operating expenses	2,014,000	2,194,000	4,086,000	4,236,000
Operating loss	(903,000)	(1,429,000)	(1,739,000)	(2,947,000)
Non-operating income:
Interest income, net	6,000	15,000	26,000	25,000
Non-operating income	6,000	15,000	26,000	25,000
Net loss	(897,000)	(1,414,000)	(1,713,000)	(2,922,000)
Preferred stock dividends	(2,000)	(2,000)	(5,000)	(5,000)
Net loss applicable to common shareholders	$ (899,000)	$ (1,416,000)	$ (1,718,000)	$ (2,927,000)
Basic and diluted loss per share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.03)	$ (0.04)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	67,388	67,331	67,388	66,743

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,713,000)	$ (2,922,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	77,000	65,000
Gain on equipment disposals		(23,000)
Amortization of other assets	20,000	25,000
Accretion of asset retirement obligation	15,000	16,000
Gain on change in ARO estimate due to lease modification	(73,000)
Share-based compensation	185,000	190,000
Changes in operating assets and liabilities:
Accounts receivable, net	(255,000)	85,000
Inventory	13,000	53,000
Prepaid expenses and other current assets	(190,000)	(20,000)
Accounts payable and accrued expenses	(51,000)	(195,000)
Accrued protocol expense	(109,000)	36,000
Accrued radioactive waste disposal	15,000	18,000
Accrued payroll and related taxes	114,000	(35,000)
Accrued vacation	21,000	(19,000)
Net cash used by operating activities	(1,931,000)	(2,726,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(204,000)	(225,000)
Proceeds from sale of equipment		23,000
Proceeds from maturity of certificates of deposit		4,418,000
Purchases of and interest from U.S. Treasury Securities		(8,259,000)
Net cash used by investing activities	(204,000)	(4,043,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(11,000)	(11,000)
Proceeds from sales of common stock, pursuant to registered direct offering, net		7,381,000
Net cash (used) provided by financing activities	(11,000)	7,370,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	(2,146,000)	601,000
Cash, cash equivalents, and restricted cash beginning of period	5,507,000	2,781,000
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	3,361,000	3,382,000
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	3,180,000	3,201,000
Restricted cash	181,000	181,000
Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cash flows	3,361,000	3,382,000
Non-cash investing and financing activities:
Recognition of operating lease liability and right of use asset	1,228,000
Warrants issued to placement agent of registered direct offering		$ 163,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	$ 84,322	$ (79,348)	$ 5,030
Issuance of common stock pursuant to registered direct offering, net (in shares)		11,000,000
Issuance of common stock pursuant to registered direct offering, net		$ 11	7,483		7,494
Share-based compensation			93		93
Net loss				(1,508)	(1,508)
Share-based compensation			93		93
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67	91,898	(80,856)	11,109
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	84,322	(79,348)	5,030
Net loss					(2,922)
Balances (in shares) at Dec. 31, 2018	59,065	67,331,147
Balances at Dec. 31, 2018		$ 67	91,868	(82,270)	9,665
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67	91,898	(80,856)	11,109
Share-based compensation			97		97
Net loss				(1,414)	(1,414)
Offering costs pursuant to registered direct offering, net			(116)		(116)
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			97		97
Balances (in shares) at Dec. 31, 2018	59,065	67,331,147
Balances at Dec. 31, 2018		$ 67	91,868	(82,270)	9,665
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	92,105	(84,492)	7,680
Share-based compensation			91		91
Net loss				(816)	(816)
Share-based compensation			91		91
Balances (in shares) at Sep. 30, 2019	59,065	67,388,047
Balances at Sep. 30, 2019		$ 67	92,196	(85,308)	6,955
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	92,105	(84,492)	7,680
Net loss					(1,713)
Balances (in shares) at Dec. 31, 2019	59,065	67,388,047
Balances at Dec. 31, 2019		$ 67	92,279	(86,205)	6,141
Balances (in shares) at Sep. 30, 2019	59,065	67,388,047
Balances at Sep. 30, 2019		$ 67	92,196	(85,308)	6,955
Share-based compensation			94		94
Net loss				(897)	(897)
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			94		94
Balances (in shares) at Dec. 31, 2019	59,065	67,388,047
Balances at Dec. 31, 2019		$ 67	$ 92,279	$ (86,205)	$ 6,141

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries, referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10 June 30, 2019. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not may 2020 0%.

Note 2 - New Accounting Standar

Note 2 - New Accounting Standards	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	2. New Accounting Standards Accounting Standards Updates Adopted In February 2016, 2016 02 842 December 15, 2018 first June 30, 2020. Accounting Standards Updates to Become Effective in Future Periods In November 2018, 2018 18, 808 808 606, 606. December 15, 2019, Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Loss Per Share

Note 3 - Loss Per Share	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does not December 31, 2019 2018, not Securities not December 31, 2019 2018, December 31, 2019 2018 Series B preferred stock 59 59 Common stock warrants 6,080 6,080 Common stock options 4,651 3,917 Total potential dilutive securities 10,790 10,056

Note 4 - Inventory

Note 4 - Inventory	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consisted of the following at December 31, 2019 June 30, 2019 ( December 31, June 30, 2019 2019 Raw materials $ 372 $ 333 Work in process 166 166 Finished goods 7 31 Total inventory, current $ 545 $ 530 December 31, June 30, 2019 2019 Enriched barium, non-current $ 116 $ 117 Raw materials, non-current 11 38 Total inventory, non-current $ 127 $ 155 Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 131 4,000 131. three six December 31, 2019, no 31 131 December 31, 2019, 894 60 twelve 834 December 31, 2020. no third 131

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment consisted of the following at December 31, 2019 June 30, 2019 ( December 31, June 30, 2019 2019 Land $ 366 $ 366 Equipment 3,873 3,825 Leasehold improvements 4,143 4,143 Other 1 801 645 Property and equipment 9,183 8,979 Less accumulated depreciation (7,447 ) (7,370 ) Property and equipment, net $ 1,736 $ 1,609 1 not no December 31, 2019 June 30, 2019 $207,000

Note 6 - Share-Based Compensati

Note 6 - Share-Based Compensation	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	6. Share-Based Compensation The following table presents the share-based compensation expense recognized for stock-based options during the three December 31, 2019 2018 Three Months 2019 2018 Cost of sales $ 8 $ 10 Research and development expenses 19 18 Sales and marketing expenses 24 22 General and administrative expenses 43 47 Total share-based compensation $ 94 $ 97 The following table presents the share-based compensation expense recognized for stock-based options during the six December 31, 2019 2018 Six Months 2019 2018 Cost of sales $ 16 $ 20 Research and development expenses 38 36 Sales and marketing expenses 49 44 General and administrative expenses 82 90 Total share-based compensation $ 185 $ 190 As of December 31, 2019, $454,000 .91 A summary of stock options within the Company’s share-based compensation plans as of December 31, 2019 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of December 31, 2019 Options Price Term (Years) Value Outstanding 4,651 $ .64 7.46 $ 418 Vested and expected to vest 4,651 $ .64 7.46 $ 418 Vested and exercisable 2,956 $ .74 6.71 $ 172 There were no three December 31, 2019 2018, There were 30,000 155,000 $11,000 $52,000 three December 31, 2019 2018, There were no three December 31, 2019 2018, There were no 32,000 three December 31, 2019 2018, There were no six December 31, 2019 2018, There were 40,000 237,500 $14,000 $87,000 six December 31, 2019 2018, There were 8,250 10,000 six December 31, 2019 2018, There were 26,250 70,750 six December 31, 2019 2018,

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Isotope Purchase Agreement In December 2015, 131 one 131. March 31, 2017, December 2016 December 31, 2017. October 23, 2017, 131 December 31, 2018. December 24, 2018, December 31, 2019 131. 131 May 31, 2019. July 11, 2019, August 4, 2019. July 30, 2019, August 2019 December 2020 131

Note 8 - Fair Value Measurement

Note 8 - Fair Value Measurements	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	8. Fair Value Measurements The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands): Fair Value at December 31, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,180 $ 3,180 $ - $ - Fair Value at June 30, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,326 $ 5,326 $ - $ - The Company’s cash and cash equivalent instruments are classified within Level 1

Note 9 - Leases

Note 9 - Leases	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in September 2007. 15,000 2015, 2017 April 30, 2021, twelve six July 2019, April 20, 2026, April 2020, eighteen $40,000 May 1, 2022. 842 July 1, 2019, $ 1.2 April 2024 $20,000. 6% not December 31, 2019 4.3 6%, For the three six December 31, 2019, $73,000 $147,000, $56,000 $111,000 three six December 31, 2019, $55,000 $109,000 three six December 31, 2019. December 31, 2019 ( Year Ending June 30, 2020 (remaining nine months of the year) $ 145 2021 290 2022 290 2023 290 2024 237 Total 1,252 Less: Imputed Interest (134 ) Total Lease Liability 1,118 Less current portion (229 ) Non-current Lease Liability $ 889 Asset Retirement Obligation The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. In connection with the lease modification executed in July 2019, Six months ended December 31, 2019 2018 Beginning balance $ 621 $ 590 Accretion of discount 15 16 Gain on change in ARO estimate due to lease modification (73 ) - Ending Balance $ 563 $ 606 The original facility lease was scheduled to expire in the fourth 2016. six December 31, 2019, five $555,000 $73,000 six December 31, 2019. $704,000 5.1%.

Note 10 - Shareholders' Equity

Note 10 - Shareholders' Equity	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10 . Shareholders’ Equity On July 11, 2018, 11,000,000 $0.75, $8.25 $0.75 In a concurrent private placement, the Company sold to each Investor, at no 50% 5,500,000 $0.75 January 11, 2019 January 11, 2024 ( 330,000 $0.9375, January 11, 2019 July 10, 2023, The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000

Note 11 - Contracts With Custom

Note 11 - Contracts With Customers	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11. Contracts with Customers We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do not no not not not not not Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic – direct sales of products and services. 2. International – direct sales of products and services. During the three December 31, 2019, not three December 31, 2018. During the six December 31, 2019, not six December 31, 2018. For the three December 31, 2019 2018, 89% 11% For the six December 31, 2019 2018, 89% 11% Contract Balances We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not not Returns Generally, we allow returns if not may 50% Significant Judgments in the Application of the Guidance in ASC 606 There are no Commissions and Contract Costs We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not Concentration of Customers One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% 10% no 10% one Six Months Ended December 31, Facility 2019 revenue 2018 revenue El Camino, Los Gatos, & other facilities 23.60 % 22.26

Note 3 - Loss Per Share (Tables

Note 3 - Loss Per Share (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2019 2018 Series B preferred stock 59 59 Common stock warrants 6,080 6,080 Common stock options 4,651 3,917 Total potential dilutive securities 10,790 10,056

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, June 30, 2019 2019 Raw materials $ 372 $ 333 Work in process 166 166 Finished goods 7 31 Total inventory, current $ 545 $ 530
Schedule of Inventory, Noncurrent [Table Text Block]	December 31, June 30, 2019 2019 Enriched barium, non-current $ 116 $ 117 Raw materials, non-current 11 38 Total inventory, non-current $ 127 $ 155

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, June 30, 2019 2019 Land $ 366 $ 366 Equipment 3,873 3,825 Leasehold improvements 4,143 4,143 Other 1 801 645 Property and equipment 9,183 8,979 Less accumulated depreciation (7,447 ) (7,370 ) Property and equipment, net $ 1,736 $ 1,609

Note 6 - Share-Based Compensa_2

Note 6 - Share-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months 2019 2018 Cost of sales $ 8 $ 10 Research and development expenses 19 18 Sales and marketing expenses 24 22 General and administrative expenses 43 47 Total share-based compensation $ 94 $ 97 Six Months 2019 2018 Cost of sales $ 16 $ 20 Research and development expenses 38 36 Sales and marketing expenses 49 44 General and administrative expenses 82 90 Total share-based compensation $ 185 $ 190
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of December 31, 2019 Options Price Term (Years) Value Outstanding 4,651 $ .64 7.46 $ 418 Vested and expected to vest 4,651 $ .64 7.46 $ 418 Vested and exercisable 2,956 $ .74 6.71 $ 172

Note 8 - Fair Value Measureme_2

Note 8 - Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value at December 31, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,180 $ 3,180 $ - $ - Fair Value at June 30, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,326 $ 5,326 $ - $ -

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending June 30, 2020 (remaining nine months of the year) $ 145 2021 290 2022 290 2023 290 2024 237 Total 1,252 Less: Imputed Interest (134 ) Total Lease Liability 1,118 Less current portion (229 ) Non-current Lease Liability $ 889
Schedule of Change in Asset Retirement Obligation [Table Text Block]	Six months ended December 31, 2019 2018 Beginning balance $ 621 $ 590 Accretion of discount 15 16 Gain on change in ARO estimate due to lease modification (73 ) - Ending Balance $ 563 $ 606

Note 11 - Contracts With Cust_2

Note 11 - Contracts With Customers (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Six Months Ended December 31, Facility 2019 revenue 2018 revenue El Camino, Los Gatos, & other facilities 23.60 % 22.26

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)	6 Months Ended
	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 3 - Loss Per Share - Antid

Note 3 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities (in shares)	10,790	10,056
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)	6,080	6,080
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	4,651	3,917

Note 4 - Inventory - Current In

Note 4 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Raw materials	$ 372	$ 333
Work in process	166	166
Finished goods	7	31
Total inventory, current	$ 545	$ 530

Note 4 - Inventory - Noncurrent

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Total inventory, non-current	$ 127	$ 155
Enriched Barium Inventory [Member]
Total inventory, non-current	116	117
Raw Materials [Member]
Total inventory, non-current	$ 11	$ 38

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Depreciation, Total	$ 77,000	$ 65,000
Other [Member]
Depreciation, Total	0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work	$ 207,000		$ 207,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Dec. 31, 2019	Jun. 30, 2019
Property and equipment, gross		$ 9,183	$ 8,979
Less accumulated depreciation		(7,447)	(7,370)
Property and equipment, net		1,736	1,609
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		3,873	3,825
Leasehold Improvements [Member]
Property and equipment, gross		4,143	4,143
Other [Member]
Property and equipment, gross	[1]	$ 801	$ 645
[1]	Includes plant and equipment not placed in service which are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at December 31, 2019 and June 30, 2019 are costs associated with advance planning and design work on the Company’s new production facility of $207,000.

Note 6 - Share-Based Compensa_3

Note 6 - Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 454,000		$ 454,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			332 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	30,000	155,000	40,000	237,500
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 11,000	$ 52,000	$ 14,000	$ 87,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0	0	8,250	10,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	0	32,000	26,250	70,750

Note 6 - Share-Based Compensa_4

Note 6 - Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Share-based compensation	$ 94	$ 97	$ 185	$ 190
Cost of Sales [Member]
Share-based compensation	8	10	16	20
Research and Development Expense [Member]
Share-based compensation	19	18	38	36
Selling and Marketing Expense [Member]
Share-based compensation	24	22	49	44
General and Administrative Expense [Member]
Share-based compensation	$ 43	$ 47	$ 82	$ 90

Note 6 - Share-Based Compensa_5

Note 6 - Share-Based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Outstanding (in shares) | shares	4,651
Outstanding, weighted exercise price (in dollars per share) | $ / shares	$ 0.64
Outstanding, weighted average contractual term (Year)	7 years 167 days
Outstanding, intrinsic value | $	$ 418
Vested and expected to vest, Options (in shares) | shares	4,651
Vested and expected to vest, weighted exercise price (in dollars per share) | $ / shares	$ 0.64
Vested and expected to vest, weighted average contractual term (Year)	7 years 167 days
Vested and expected to vest, intrinsic value | $	$ 418
Vested and exercisable (in shares) | shares	2,956
Vested and exercisable, weighted exercise price (in dollars per share) | $ / shares	$ 0.74
Vested and exercisable, weighted average contractual term (Year)	6 years 259 days
Vested and exercisable, intrinsic value | $	$ 172

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Details Textual)	1 Months Ended
	Dec. 31, 2015
Purchase Agreement Period	1 year

Note 8 - Fair Value Measureme_3

Note 8 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Cash and cash equivalents	$ 3,180	$ 5,326
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	3,180	5,326
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2024USD ($)	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)	Jul. 31, 2019USD ($)	Jul. 01, 2019USD ($)	Jun. 30, 2019USD ($)
Operating Lease, Right-of-Use Asset		$ 1,116,000		$ 1,116,000
Operating Lease, Liability, Total		$ 1,118,000		$ 1,118,000
Operating Lease, Weighted Average Discount Rate, Percent		6.00%		6.00%
Operating Lease, Weighted Average Remaining Lease Term		4 years 109 days		4 years 109 days
Operating Lease, Expense		$ 73,000		$ 147,000
Operating Lease, Right-of-use Asset, Amortization		56,000		111,000
Increase (Decrease) in Operating Lease Liability		$ 55,000		$ 109,000
Lessee, Operating Lease, Renewal Term		5 years		5 years
Asset Retirement Obligation, After Adjustment		$ 555,000		$ 555,000
Gain (Loss) on Change in ARO Estimate				73,000
ARO Original Obligation Amount						$ 704,000
ARO Discount Amount Interest Rate						$ 5.10
Forecast [Member]
Termination of Lease, Penalty	$ 20,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset							$ 1,200,000
Operating Lease, Liability, Total							$ 1,200,000
Operating Lease, Weighted Average Discount Rate, Percent							6.00%
Maximum [Member]
Operating Lease Arrangement, Maximum Early Termination Penalty		$ 40,000		$ 40,000
Applied Process Engineering Laboratory [Member]
Area of Real Estate Property | ft²		15,000		15,000

Note 9 - Leases - Future Operat

Note 9 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
2020 (remaining nine months of the year)	$ 145
2021	290
2022	290
2023	290
2024	237
Total	1,252
Less: Imputed Interest	(134)
Total Lease Liability	1,118
Less current portion	(229)
Non-current Lease Liability	$ 889

Note 9 - Leases - Asset Retirem

Note 9 - Leases - Asset Retirement Obligation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Beginning balance			$ 621,000	$ 590,000
Accretion of discount			15,000	16,000
Gain on change in ARO estimate due to lease modification			(73,000)
Ending Balance	$ 563,000	$ 606,000	$ 563,000	$ 606,000

Note 10 - Shareholders' Equity

Note 10 - Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 11, 2018	Dec. 31, 2019	Dec. 31, 2018
Proceeds from Issuance of Common Stock			$ 7,381
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,830,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	11,000,000
Shares Issued, Price Per Share	$ 0.75
Proceeds from Issuance of Common Stock	$ 8,250
Payments of Stock Issuance Costs	$ 750
Class of Warrant Or Right, Authorized, Percentage	50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Private Placement [Member] | H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	330,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9375

Note 11 - Contracts With Cust_3

Note 11 - Contracts With Customers (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Restocking Fee, Percentage	50.00%		50.00%
Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	89.00%	89.00%
Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	11.00%	11.00%
Geographic Distribution, Foreign [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total	$ 0		$ 0

Note 11 - Contracts With Cust_4

Note 11 - Contracts With Customers - Concentration of Customers (Details)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | El Camino, Los Gatos, & Other Facilities [Member]
Concentration Risk, Percentage	23.60%	22.26%